RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
RAPA-201-RRMM is a medical study for adults with a type of cancer called multiple myeloma that has come back after treatment and is not responding well to medicine. The study is for people who have already tried at least three different kinds of treatment. It will test a new treatment where doctors take cells from the person's own body and use them to make a special kind of medicine to fight the cancer. The study will be done at multiple medical centers.
RAPA-201-RRMM is a medical study for adults with a type of cancer called multiple myeloma that has come back after treatment and is not responding well to medicine. The study is for people who have already tried at least three different kinds of treatment. It will test a new treatment where doctors take cells from the person's own body and use them to make a special kind of medicine to fight the cancer. The study will be done at multiple medical centers.
*Third Opinion AI Generated Synopsis
Trial Summary
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: